Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

27. März 2014 21:40 ET | Quelle: Prima BioMed

Prima BioMed's CVac(TM) Data Demonstrating Improvement in PFS in Second Remission Ovarian Cancer Accepted for Oral Presentation at ASCO

SYDNEY, AUSTRALIA--(Marketwired - Mar 27, 2014) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima") announced today that the American Society of Clinical Oncology has accepted the abstract...
25. März 2014 09:37 ET | Quelle: Prima BioMed

Prima BioMed Announces Significant Updates to Its Clinical Advisory Board: Eric Pujade-Lauraine, Christian Marth, and Ignace Vergote Join Esteemed Group of Gynecology Oncology Advisors

SYDNEY, AUSTRALIA--(Marketwired - Mar 25, 2014) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima," "the Company") announced today that Professors Eric Pujade-Lauraine, MD, PhD, Christian Marth,...
05. März 2014 09:23 ET | Quelle: Prima BioMed

$1.6 Million R&D Tax Incentive Refund Received

SYDNEY, AUSTRALIA--(Marketwired - Mar 5, 2014) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima," "the Company") is pleased to advise that it has received approximately...
26. Februar 2014 20:15 ET | Quelle: Prima BioMed

Prima BioMed to Present at Regen Med Investor Day March 26th in New York

SYDNEY, AUSTRALIA--(Marketwired - Feb 26, 2014) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima," "the Company") will present at the 2nd Annual Regen Med Investor Day to be held Wednesday,...
26. Februar 2014 17:30 ET | Quelle: Prima BioMed

Prima BioMed to Present at 24th Annual Wall Street Analyst Forum Institutional Investor Conference

SYDNEY, AUSTRALIA--(Marketwired - Feb 26, 2014) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima," "the Company") will present a corporate overview and provide an update of its CVac™...
20. Februar 2014 17:07 ET | Quelle: Prima BioMed

Prima BioMed and Neopharm Group Execute Final Agreement for CVac License

SYDNEY, AUSTRALIA--(Marketwired - Feb 20, 2014) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", the "Company") is pleased to announce that it has finalized an agreement with Neopharm Group...
19. Februar 2014 19:05 ET | Quelle: Prima BioMed

Dr. Bradley J. Monk to Join Prima BioMed's Clinical Advisory Board

SYDNEY, AUSTRALIA--(Marketwired - Feb 19, 2014) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima," "the Company") announced today that Bradley J. Monk, MD, an esteemed clinical researcher and...
11. Februar 2014 18:45 ET | Quelle: Prima BioMed

Pete A. Meyers to Join Prima BioMed's Board of Directors

SYDNEY, AUSTRALIA--(Marketwired - Feb 11, 2014) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", the "Company") is pleased to announce that Pete A. Meyers will join Prima's Board as a...
05. Februar 2014 17:00 ET | Quelle: Prima BioMed

Prima BioMed's CAN-004 Clinical Trial Amendment Approved in Multiple Jurisdictions

SYDNEY, AUSTRALIA--(Marketwired - Feb 5, 2014) - Prima BioMed Ltd. (ASX: PRR) (NASDAQ: PBMD) ("Prima," the "Company") announced that multiple jurisdictions have approved its amended CAN-004...
30. Januar 2014 21:20 ET | Quelle: Prima BioMed

Prima BioMed to Present at the 16th Annual BIO CEO & Investor Conference

SYDNEY, AUSTRALIA--(Marketwired - Jan 30, 2014) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", "the Company") has announced today that Matthew Lehman, its Chief...

Vorherige Seite

Nächste Seite